Presentation is loading. Please wait.

Presentation is loading. Please wait.

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

Similar presentations


Presentation on theme: "An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist."— Presentation transcript:

1 An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)  C. Michael Gibson, MS, MD, Roxana Mehran, MD, Christoph Bode, MD, Johnathan Halperin, MD, Freek Verheugt, MD, Peter Wildgoose, PhD, Martin van Eickels, MD, Gregory Y.H. Lip, MD, Marc Cohen, MD, Steen Husted, MD, Eric Peterson, MD, Keith Fox, MD  American Heart Journal  Volume 169, Issue 4, Pages e5 (April 2015) DOI: /j.ahj Copyright © 2014 Elsevier Inc. Terms and Conditions

2 Figure Study design of PIONEER AF-PCI.
American Heart Journal  , e5DOI: ( /j.ahj ) Copyright © 2014 Elsevier Inc. Terms and Conditions


Download ppt "An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist."

Similar presentations


Ads by Google